Reuters - Acadia Pharmaceuticals Inc (ACAD.O) shares rose as much as 44 percent to a year-high on Friday, amid speculation of an imminent release of data from a late-stage trial of its experimental drug for psychosis brought on by Parkinson’s disease.
